References
diabetes, TG, peripheral artery disease
PERIPHERAL ARTERY DISEASE, CARDIOVASCULAR DISEASE, CVD, PAD, REGRESSION, DIABETES
Flowchart of the patient selection process. Following the 3-month evaluation, 16 out of the 19 patients in the control group continued to receive treatment with low-dose EPA/DHA for an additional 3 months. DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid.Changes in the (Correlation between the changes in RLP-C levels and ABI values in the (Participant characteristics.Data are expressed as the mean ± standard deviation, median (interquartile range), or number (percentage). DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; HDL: high-density lipoprotein; LDL: low-density lipoprotein; RLP: remnant-like lipoprotein; CRP: c-reactive protein; CVD: cardiovascular disease; PAD: peripheral artery disease. The differences between the EPA/DHA and control groups were evaluated using the Student’s Changes in lipid and inflammatory profiles after 3 months.Data are expressed as the mean ± standard deviation. DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, HDL: high-density lipoprotein; LDL: low-density lipoprotein; RLP: remnant-like lipoprotein; CRP: c-reactive protein. The differences between the EPA/DHA and control groups were evaluated using the Student’s Multiple regression analysis of the association between the changes in RLP-C levels and the ABI.Model 1: no adjustment. Model 2: adjusted for age, sex, duration of hemodialysis, history of diabetes, and statin use. Model 3: adjusted for the variables in Model 2 plus the baseline SBP, TG, LDL-C, HDL-C, EPA, and DHA levels.